Geranylgeranyltransferase Activity Research Articles

Prenylation is required for polar cell elongation, cell adhesion, and differentiation in Physcomitrella patens

Protein prenylation is required for a variety of growth and developmental processes in flowering plants. Here we report the consequences of loss of function of all known prenylation subunits in the moss Physcomitrella patens. As in Arabidopsis, protein farnesyltransferase and protein geranylgeranyltransferase type I are not required for viability. However, protein geranylgeranyltransferase type I activity is required for cell adhesion, polar cell elongation, and cell differentiation. Loss of protein geranylgeranyltransferase activity results in colonies of round, single-celled organisms that resemble unicellular algae. The loss of protein farnesylation is not as severe but also results in polar cell elongation and differentiation defects. The complete loss of Rab geranylgeranyltransferase activity appears to be lethal in P.patens. Labeling with antibodies to cell wall components support the lack of polarity establishment and the undifferentiated state of geranylgeranyltransferase type I mutant plants. Our results show that prenylated proteins play key roles in P.patens development and differentiation processes.

Tu1853 Geranylgeranyltransferase Activity in Gut Epithelial Cells is Essential for Intestinal Homeostasis

Tu1853 Geranylgeranyltransferase Activity in Gut Epithelial Cells is Essential for Intestinal Homeostasis

Differential Differentiation- and Survival and Invasion-related T-/Hcadherin (CDH13) Computational Downstream Network from No-Tumor Hepatitis/Cirrhosis (HBV or HCV infection) to Human Hepatocellular Carcinoma (HCC) Malignant Transformation

We constructed and analyzed the low-and high-expression (fold change ≥2) different-activated and -inhibited T-/H-cadherin (CDH13) downstream network from no-tumor hepatitis/cirrhosis (HBV or HCV infection) to HCC malignant transformation in GEO data set by integration of gene regulatory network inference method based on linear programming and decomposition procedure with GO database. Our results show that the low-expression CDH13 downstream network has the multi-activated and -inhibited molecular pattern in no-tumor hepatitis/cirrhosis, whereas high-expression CDH13 downstream mainly somewhat inhibited molecular connections but significant reduced network (fold ≥2) in HCC. We suppose that the low-expression CDH13 downstream network mainly activates cell differentiation cell adhesion, but inhibits nuclear chromosome, mitosis in no-tumor hepatitis/cirrhosis, whereas the high-expression CDH13 downstream network activates Rab-protein geranylgeranyltransferase activity, protein modification, but inhibits modification-dependent protein catabolism and nucleotide binding in HCC. We put forward hypothesis that low-expression CDH13 activates cadherin binding, homophilic cell adhesion, negative regulation of cell adhesion, positive regulation of calcium-mediated signaling, calcium-dependent cell-cell adhesion, positive regulation of cell-matrix adhesion, low density lipoprotein mediated signaling and inhibits regulation of endothelial cell proliferation, positive regulation of smooth muscle cell proliferation, keratinocyte proliferation, as a result of inducing differentiation in no-tumor hepatitis/cirrhosis, whereas high-expression CDH13 activates positive regulation of survival gene product activity, protein homodimerization activity, Rho protein signal transduction, Rac protein signal transduction, positive regulation of cell migration, sprouting angiogenesis, positive regulation of positive chemotaxis, epidermal growth factor receptor signaling pathway, endothelial cell migration, lamellipodium biogenesis, and inhibits regulation of endocytosis, caveola, as a result of inducing survival and invasion in HCC. Our inferences are consistent with different-activated and -inhibited CDH13 downstream network, GO database and literatures, respectively.

Aplexone targets the HMG-CoA reductase pathway and differentially regulates arteriovenous angiogenesis

Arterial and venous endothelial cells exhibit distinct molecular characteristics at early developmental stages. These lineage-specific molecular programs are instructive to the development of distinct vascular architectures and physiological conditions of arteries and veins, but their roles in angiogenesis remain unexplored. Here, we show that the caudal vein plexus in zebrafish forms by endothelial cell sprouting, migration and anastomosis, providing a venous-specific angiogenesis model. Using this model, we have identified a novel compound, aplexone, which effectively suppresses venous, but not arterial, angiogenesis. Multiple lines of evidence indicate that aplexone differentially regulates arteriovenous angiogenesis by targeting the HMG-CoA reductase (HMGCR) pathway. Treatment with aplexone affects the transcription of enzymes in the HMGCR pathway and reduces cellular cholesterol levels. Injecting mevalonate, a metabolic product of HMGCR, reverses the inhibitory effect of aplexone on venous angiogenesis. In addition, aplexone treatment inhibits protein prenylation and blocking the activity of geranylgeranyl transferase induces a venous angiogenesis phenotype resembling that observed in aplexone-treated embryos. Furthermore, endothelial cells of venous origin have higher levels of proteins requiring geranylgeranylation than arterial endothelial cells and inhibiting the activity of Rac or Rho kinase effectively reduces the migration of venous, but not arterial, endothelial cells. Taken together, our findings indicate that angiogenesis is differentially regulated by the HMGCR pathway via an arteriovenous-dependent requirement for protein prenylation in zebrafish and human endothelial cells.

Protein geranylgeranyltransferase-I of Trypanosoma cruzi

Protein geranylgeranyltransferase type I (PGGT-I) and protein farnesyltransferase (PFT) occur in many eukaryotic cells. Both consist of two subunits, the common α subunit and a distinct β subunit. In the gene database of protozoa Trypanosoma cruzi, the causative agent of Chagas’ disease, a putative protein that consists of 401 amino acids with ∼20% amino acid sequence identity to the PGGT-I β of other species was identified, cloned, and characterized. Multiple sequence alignments show that the T. cruzi ortholog contains all three of the zinc-binding residues and several residues uniquely conserved in the β subunit of PGGT-I. Co-expression of this protein and the α subunit of T. cruzi PFT in Sf9 insect cells yielded a dimeric protein that forms a tight complex selectively with [ 3H]geranylgeranyl pyrophosphate, indicating a key characteristic of a functional PGGT-I. Recombinant T. cruzi PGGT-I ortholog showed geranylgeranyltransferase activity with distinct specificity toward the C-terminal CaaX motif of protein substrates compared to that of the mammalian PGGT-I and T. cruzi PFT. Most of the CaaX-containing proteins with X = Leu are good substrates of T. cruzi PGGT-I, and those with X = Met are substrates for both T. cruzi PFT and PGGT-I, whereas unlike mammalian PGGT-I, those with X = Phe are poor substrates for T. cruzi PGGT-I. Several candidates for T. cruzi PGGT-I or PFT substrates containing the C-terminal CaaX motif are found in the T. cruzi gene database. Among five C-terminal peptides of those tested, a peptide of a Ras-like protein ending with CVLL was selectively geranylgeranylated by T. cruzi PGGT-I. Other peptides with CTQQ (Tcj2 DNAJ protein), CAVM (TcPRL-1 protein tyrosine phosphatase), CHFM (a small GTPase like protein), and CQLF (TcRho1 GTPase) were specific substrates for T. cruzi PFT but not for PGGT-I. The mRNA and protein of the T. cruzi PGGT-I β ortholog were detected in three life-cycle stages of T. cruzi. Cytosol fractions from trypomastigotes (infectious mammalian stage) and epimastigotes (insect stage) were shown to contain levels of PGGT-I activity that are ∼100-fold lower than PFT activity. The CaaX mimetics known as PGGT-I inhibitors show very low potency against T. cruzi PGGT-I compared to the mammalian enzyme, suggesting the potential to develop selective inhibitors against the parasite enzyme.

RhoA-dependent PAI-1 gene expression induced in endothelial cells by monocyte adhesion mediates geranylgeranyl transferase I and Ca 2+ signaling

We investigated the role of RhoA activation and its mechanism in plasminogen activator inhibitor-1 (PAI-1) gene expression induced in endothelial cells by monocyte adhesion. Isolated human peripheral blood monocytes were added to cultured human coronary endothelial cells. Monocyte adhesion to endothelial cells increased PAI-1 expression at the transcriptional level and activated RhoA which was accompanied by an increase in the activity of geranylgeranyl transferase I (GGTase I), an enzyme responsible for geranylgeranylation, and actin stress fiber formation. Inhibition of RhoA by C3 exoenzyme or by adenovirus-mediated expression of N19RhoA, as well as by pravastatin, prevented the upregulation of PAI-1 induced by monocyte adhesion. GGTI-286, an inhibitor of GGTase I, prevented the monocyte-induced RhoA activation and PAI-1 expression in endothelial cells. Monocyte attachment induced an increase in intracellular Ca 2+ concentration ([Ca 2+] i) in endothelial cells and Ca 2+ chelation prevented the increased promoter activity and expression of PAI-1 induced by monocyte adhesion. C3 exoenzyme and GGTI-286 also suppressed endothelial intracellular Ca 2+ mobilization and Ca 2+ entry induced by monocytes. The present study shows that GGTase I plays a role in the RhoA activation in endothelial cells induced by monocyte adhesion and that GGTase I-mediated Ca 2+ signaling may contribute to RhoA-dependent PAI-1 gene expression.

Spectroscopic study of fluorescent peptides for prenyl transferase assays

A study of the prenyl transferase reactions was performed by fluorescence using rat brain cytosol fractions as an enzyme source. Four dansylated peptides corresponding to the C-terminal sequence of Ras isoforms were synthesised. The effects of different detergents on the farnesylation or geranylgeranylation of the four peptides were evaluated. Dose-dependent effects of dodecyl-maltoside, a non-ionic detergent, on the farnesyl transferase or geranylgeranyl transferase activities were observed with all peptide substrates. Additionally, the effect of temperature was investigated and these assays were applied to determine Michaelis–Menten constants ( K m) of the substrates: dansyl-GCVLS (1.8 μM), dansyl-GCVVM (3.2 μM), dansyl-CVIM (3.4 μM) and dansyl-GCVLL (8.4 μM) and FPP (22.6 μM) for FTase activity. Using GGPP as co-substrate, GGTase activity was measured with K m values superior to 50 μM for all the three substrate dansyl-GCVLS, dansyl-GCVVM, or dansyl-CVIM, whereas values of 7.6 and 5.4 μM were calculated for the dansyl-GCVLL sequence and GGPP co-substrate, respectively. IC 50 values of selective prenyl transferase inhibitors, B-581, FTI 276 and GGTI 287 have been measured to 34, 0.8 and 18 nM, respectively, using dansyl-GCVLS as substrate (FTase inhibition). When dansyl-GCVLL is used as substrate (GGTase inhibition) the IC 50 values are 5100, 75 and 5 nM for B-581, FTI 276 and GGTI 287, respectively. Then, this developed method allowed to evaluate the selectivity of all the three inhibitors tested.

Isoprenoid-mediated control of SMAD3 expression in a cultured model of cystic fibrosis epithelial cells.

Several cellular signaling alterations have been identified in cystic fibrosis (CF) epithelium. One of these alterations is reduced SMAD3 protein expression and a corresponding reduction in SMAD3-mediated transforming growth factor-beta1 (TGF-beta1) signaling in CF epithelial cells compared with wild-type (wt) controls. The goal of this study was to identify a mechanism leading to reduced SMAD3 protein expression in CF epithelium. Based on previous work demonstrating isoprenoid-mediated regulation of CF-related alterations in signal transducer and activator of transcription-1 (Stat1) and inducible nitric oxide synthase (NOS2) expression, the hypothesis of this study is that inhibition of isoprenoid-dependent signaling will restore SMAD3 expression and signaling in a model of CF epithelium. Presented data will demonstrate that inhibition of both farnesyl and geranylgeranyl transferase activities partially restores SMAD3-mediated TGF-beta1 signaling and normalizes SMAD3 protein expression in one cultured model of CF cells. Analysis of the human SMAD3 promoter demonstrates that isoprenoid regulation of SMAD3 expression is dependent on Sp1/Sp3 activity, although farnesyl-mediated pathways may be acting through a secondary mechanism as well. Isoprenoid-mediated regulation of SMAD3 expression, coupled with previous data demonstrating isoprenoid control of Stat1 and NOS2 expression, suggest that the isoprenoid/cholesterol synthesis pathway is a critical intermediate in influencing CF-related cell signaling changes.

Serine Phosphorylation Negatively Regulates RhoA in Vivo

Previous work indicates that RhoA phosphorylation on Ser188 by cAMP or cGMP-dependent kinases inhibits its activity. However, these studies lacked the possibility to directly study phosphorylated RhoA activity in vivo. Therefore, we created RhoA proteins containing phosphomimetic residues in place of the cAMP/cGMP-dependent kinase phosphorylation site. RhoA phosphorylation or phosphomimetic substitution did not affect Rho guanine nucleotide exchange factor, GTPase activating protein, or geranylgeranyl transferase activity in vitro but promoted binding to the Rho guanine-dissociation inhibitor as measured by exchange factor competition assays. The in vitro similarities between RhoA phosphomimetic proteins and phosphorylated RhoA allowed us to study function of phosphorylated RhoA in vivo. RhoA phosphomimetic proteins display depressed GTP loading when transiently expressed in NIH 3T3 cells. Stable-expressing RhoA and RhoA(S188A) clones spread significantly slower than mock-transfected or RhoA(S188E) clones. RhoA(S188A) clones were protected from the morphological effects of a cAMP agonist, whereas phosphomimetic clones exhibit stress fiber disassembly similar to control cells. Together, these data provide in vivo evidence that addition of a charged group to Ser188 upon phosphorylation negatively regulates RhoA activity and indicates that this occurs through enhanced Rho guanine-dissociation inhibitor interaction rather than direct perturbation of guanine nucleotide exchange factor, GTPase activating protein, or geranylgeranyl transferase activity.

Garlic extract methylallyl thiosulfinate blocks insulin potentiation of platelet-derived growth factor–stimulated migration of vascular smooth muscle cells

Platelet-derived growth factor (PDGF) is a potent inducer of vascular smooth muscle cell (VSMC) migration, whereas insulin, in physiological concentrations, helps maintain the nonproliferative phenotype of these cells. However, hyperinsulinemia (10 nmol/L) significantly potentiates the PDGF (30 pmol/L)-induced migration of VSMC. This potentiating effect of hyperinsulinemia appears to be mediated by increased availability of geranylgeranylated Rho-A. Hyperinsulinemia significantly increased the activity of geranylgeranyltransferase I (GGTase I) and the amounts of prenylated Rho-A. This action of hyperinsulinemia was inhibited by methylallyl thiosulfinate (MAT), a component of garlic extract, which exerted a strong anti-GGTase I activity. MAT also completely inhibited the ability of hyperinsulinemia to potentiate the PDGF-induced VSMC migration. Thus, the purported anti-atherogenic action of garlic may be related to its inhibitory influence on GGTase I. Copyright 2003, Elsevier Science (USA). All rights reserved.

Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.

Statins are inhibitors of the rate-limiting enzyme in cholesterol synthesis, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. In addition to reducing LDL cholesterol, statin treatment increases the levels of the antiatherogenic HDL and its major apolipoprotein apoA-I. Here, we investigated the molecular mechanisms of apoA-I regulation by statins. Treatment with statins increased apoA-I mRNA levels in human HepG2 hepatoma cells, and this effect was reversed by the addition of mevalonate, implicating HMG-CoA reductase as the relevant target of these drugs. Pretreatment with Actinomycin D abolished the increase of apoA-I mRNA, indicating that statins act at the transcriptional level. Indeed, statins increased the human apoA-I promoter activity in transfected cells, and we have identified a statin response element that coincides with a PPARalpha response element known to confer fibrate responsiveness to this gene. The statin effect could be abolished not only by mevalonate, but also by geranylgeranyl pyrophosphate, whereas inhibition of geranylgeranyl transferase activity or treatment with an inhibitor of the Rho GTP-binding protein family increased PPARalpha activity. Using dominant negative forms of these proteins, we found that Rho A itself mediates this response. Because cotreatment with statins and fibrates activated PPARalpha in a synergistic manner, these observations provide a molecular basis for combination treatment with statins and fibrates in coronary heart disease.

Hyperinsulinemia enhances transcriptional activity of nuclear factor-kappaB induced by angiotensin II, hyperglycemia, and advanced glycosylation end products in vascular smooth muscle cells.

Pathogenesis of macrovascular complications of diabetes may involve an activation of the transcription factor nuclear factor-kappaB (NF-kappaB) by hyperglycemia and advanced glycosylation end products (AGEs). Activation of NF-kappaB is believed to be dependent on activation of the Rho family of GTPases. Although the precise mechanism of the Rho-mediated action is not completely understood, posttranslational modification of the Rho proteins by geranylgeranylation is required for their subsequent activation. We observed that in cultured vascular smooth muscle cells (VSMCs), insulin stimulated the activity of geranylgeranyltransferase (GGTase) I and increased the amounts of geranylgeranylated Rho-A from 47% to 60% (P:<0.05). GGTI-286, an inhibitor of GGTase I, blocked both effects of insulin. Increased availability of prenylated Rho-A significantly augmented the abilities of angiotensin II (Ang II), hyperglycemia, and AGEs to activate NF-kappaB, as measured by NF-kappaB response-element luciferase reporter activity. Preincubations of VSMCs with insulin for 24 hours doubled NF-kappaB transactivation by Ang II, hyperglycemia, and AGEs. This priming effect of insulin was completely inhibited by GGTI-286. We demonstrate for the first time, to our knowledge, that insulin potentiates NF-kappaB-dependent transcriptional activity induced by hyperglycemia, AGEs, and Ang II in VSMCs by increasing the activity of GGTase I and the availability of geranylgeranylated Rho-A.

Insulin Promotes Phosphorylation and Activation of Geranylgeranyltransferase II: STUDIES WITH GERANYLGERANYLATION OF Rab-3 AND Rab-4

Rab proteins play a crucial role in the trafficking of intracellular vesicles. Rab proteins are GTPases that cycle between an inactive GDP-bound form and an active GTP-bound conformation. A prerequisite to Rab activation by GTP loading is its post-translational modification by the addition of geranylgeranyl moieties to highly conserved C-terminal cysteine residues. We examined the effect of insulin on the activity of geranylgeranyltransferase II (GGTase II) in 3T3-L1 fibroblasts and adipocytes. In fibroblasts, insulin increased the enzymatic activity of GGTase II 2.5-fold after 1 h of incubation, an effect that is blocked by perillyl alcohol, an inhibitor of prenyltransferases, but not by the geranylgeranyltransferase I inhibitor, GGTI-298, or the farnesyltransferase inhibitor, alpha-hydroxyfarnesylphosphonic acid. Concomitantly, insulin stimulated the phosphorylation of the GGTase II alpha-subunit without any effect on the GGTase II beta-subunit. At the same time, insulin also increased the amounts of geranylgeranylated Rab-3 in 3T3-L1 fibroblasts from 44 +/- 1.2% in control cells to 63 +/- 3.8 and 64 +/- 6.1% after 1 and 24 h of incubation, respectively. In adipocytes, insulin increased the amounts of geranylgeranylated Rab-4 from 38 +/- 0.6% in control cells to 56 +/- 1.7 and 60 +/- 2.6% after 1 and 24 h of incubation, respectively. In both fibroblasts and adipocytes, the presence of perillyl alcohol blocked the ability of insulin to increase geranylgeranylation of Rab-4, whereas GGTI-298 and alpha-hydroxyfarnesylphosphonic acid were without effect, indicating that insulin activates GGTase II. In summary, insulin promotes phosphorylation and activation of GGTase II in both 3T3 L1 fibroblasts and adipocytes and increases the amounts of geranylgeranylated Rab-3 and Rab-4 proteins.

Geranylgeranyl diphosphate-based inhibitors of post-translational geranylgeranylation of cellular proteins.

A novel series of stable analogs of geranylgeranyl diphosphate (GGdP) are described in which the biologically labile diphosphate moiety of GGdP is replaced by portions that can act as stable isosters. The compounds inhibited the geranylgeranyltransferase activity in whole PC-3 prostate cancer cells, as determined by the inhibition of post-translational isoprenylation of the small GTP-binding protein p21rap 1 and the accumulation of unprocessed p21rap 1 in the cytosolic fraction. However, the compounds did not affect the farnesylation of p21ras, as shown by protein immunoprecipitation after whole cell labeling with [3 H]-(R,S)-mevalonolactone. Despite the absence of effects of post-translational processing of p21ras, these compounds proved to be cytotoxic for prostate cancer cells, with half-maximal inhibition of cell growth obtained in the range 18.5-35.1 microM. The GGdP analogs described in the this study are novel, non-peptidic inhibitors of geranylgeranylation that may be active as antitumor agents.

A Fluorescence Assay for Geranylgeranyl Transferase Type I

A new fluorescence assay for measuring the activity of geranylgeranyl transferase (type I) is described. It does not require the use of either radiolabeled geranylgeranyl diphosphate or the purified recombinant Ras protein substrate with the carboxy terminal sequence of CVLL. Dansyl GCVLL and unlabeled geranylgeranyl diphosphate are used as substrates. The K m for Dansyl GCVLL and for geranylgeranyl diphosphate is 5 μM and 800 nM, respectively. At equimolar concentrations, enzymatic activity is higher when Dansyl GCVLL is used as a substrate compared to Dansyl GCVII. Dansyl GCVLS, a substrate for farnesyl transferase, is inactive in this assay. CVFL is a competitive inhibitor of geranylgeranyl transferase and exhibits a K i of 200 nM.

Lipid modification of low molecular mass GTP binding proteins

The in vitro substrate preferences of recombinant S. cerevisiae protein farnesyltransferase and type-I protein geranylgeranyltransferase were determined. Proteins ending in 16 different CaaX sequences (C = cysteine, a = aliphatic amino acid, X= variable amino acids) were used to determine the protein substrate preferences of these S. cerevisiae prenyltransferases. The identites of the attached prenyl groups were confirmed by iodomethane treatment of prenylated substrates and reverse-phase HPLC. The CaaX preference of each recombinant yeast enzyme was found to be nearly identical to the reported preferences of purified mammalian protein farnesyltransferase and type-I protein geranylgeranyltransferase. S. cerevisiae farnesyltransferase preferentially farnesylated CaaX sequences ending in methionine, cysteine or serine. The farnesyltransferase also attached geranylgeranyl to some CaaX sequences ending in methionine, leucine and cysteine. The S. cerevisiae type-I geranylgeranyltransferase preferentially geranylgeranylated CaaX sequences ending in leucine and to a lesser degree methionine. Yeast extracts were found to contain prenylating activities identical to those observed with the recombinant enzymes. Farnesyltransferase activity in yeast extracts exceeded type-I geranylgeranyltransferase activity by at least 3-fold, resulting in prenylation of leucine-ending CaaX substrates with a mixture of 75% geranylgeranyl and 25% farnesyl. These results suggest that some substrate overlap may occur between the S. cerevisiae protein farnesyltransferase and the type-I protein geranylgeranyltransferase in vivo.

The Saccharomyces cerevisiae MSI4 gene encodes the yeast counterpart of component A of Rab geranylgeranyltransferase.

We describe the isolation of MSI4 as a multicopy suppressor of ira1 (inhibitory regulator of Ras). We find it encodes a 66-kDa protein with three regions similar to component A of Rab geranylgeranyltransferase and Rab guanine nucleotide dissociation inhibitor. A gene disruption experiment showed that MSI4 is essential for cell growth. To investigate its functions further, we constructed a strain whose MSI4 is driven by the GAL1 promoter. This strain accumulated the endoplasmic reticulum precursor form of a vacuolar enzyme, carboxypeptidase Y, under the restrictive conditions. Moreover, we showed that the activity of geranylgeranyl-transferase for Ypt1p was very low in the mutant shifted to glucose medium. We propose that the MSI4 gene product is a yeast counterpart of component A of Rab geranylgeranyltransferase that is essential for Ypt1p to localize on membranes.

Substrate characterization of the saccharomyces cerevisiae protein farnesyltransferase and type-I protein geranylgeranyltransferase

The in vitro substrate preferences of recombinant S. cerevisiae protein farnesyltransferase and type-I protein geranylgeranyltransferase were determined. Proteins ending in 16 different C aaX sequences (C = cysteine, a = aliphatic amino acid, X= variable amino acids) were used to determine the protein substrate preferences of these S. cerevisiae prenyltransferases. The identites of the attached prenyl groups were confirmed by iodomethane treatment of prenylated substrates and reverse-phase HPLC. The C aaX preference of each recombinant yeast enzyme was found to be nearly identical to the reported preferences of purified mammalian protein farnesyltransferase and type-I protein geranylgeranyltransferase. S. cerevisiae farnesyltransferase preferentially farnesylated C aaX sequences ending in methionine, cysteine or serine. The farnesyltransferase also attached geranylgeranyl to some C aaX sequences ending in methionine, leucine and cysteine. The S. cerevisiae type-I geranylgeranyltransferase preferentially geranylgeranylated C aaX sequences ending in leucine and to a lesser degree methionine. Yeast extracts were found to contain prenylating activities identical to those observed with the recombinant enzymes. Farnesyltransferase activity in yeast extracts exceeded type-I geranylgeranyltransferase activity by at least 3-fold, resulting in prenylation of leucine-ending C aaX substrates with a mixture of 75% geranylgeranyl and 25% farnesyl. These results suggest that some substrate overlap may occur between the S. cerevisiae protein farnesyltransferase and the type-I protein geranylgeranyltransferase in vivo.

Isoprenylation of the plant molecular chaperone ANJ1 facilitates membrane association and function at high temperature.

We demonstrate that ANJ1, a higher plant homolog of the bacterial molecular chaperone DnaJ, is a substrate in vitro for protein farnesyl- and geranylgeranyl-transferase activities present in cell extracts of the plant Atriplex nummularia and yeast Saccharomyces cerevisiae. Isoprenylation did not occur when cysteine was replaced by serine in the CAQQ motif at the carboxyl terminus of ANJ1, indicating that this sequence functions as a CaaX consensus sequence for polyisoprenylation (where C is cysteine, a is an aliphatic residue, and X is any amino acid residue). Substitution of leucine for the terminal glutamine did not result in the expected geranylgeranylation as occurs with mammalian proteins containing a carboxyl-terminal leucine. Unlike the wild-type ANJ1, neither of the proteins containing these amino acid substitutions could functionally complement the yeast temperature-sensitive mutant mas5. Farnesylation enhanced the association of ANJ1 with A. nummularia microsomal membranes. Electrophoretic mobility of ANJ1 from the plant indicated that the protein is isoprenylated in vivo.

Ras (CXXX) and Rab (CC/CXC) prenylation signal sequences are unique and functionally distinct.

Rab proteins typically lack the consensus carboxyl-terminal CXXX motif that signals isoprenoid modification of Ras and other isoprenylated proteins and, instead, terminate in either CC or CXC sequences (C = cysteine, X = any amino acid). To compare the functional relationship between the Ras CXXX and the Rab CC/CXC motifs, we have generated chimeric Ras proteins terminating in Rab carboxyl-terminal CC or CXC sequences. These mutant Ras proteins were not isoprenylated in vitro or in vivo, demonstrating that the CC and CXC sequences alone are not sufficient to replace a CXXX sequence to signal Ras isoprenoid modification. Surprisingly, chimeric Ras/Rab proteins terminating in significant lengths of carboxyl-terminal sequences from Rab1b (7-139 residues), Rab2 (5-151 residues), or Rab3a (12 residues) were also not isoprenylated. These results demonstrate that the sequence requirements for isoprenoid modification of Rab proteins are more complex than the simple tetrapeptide CXXX sequence for isoprenoid modification of Ras proteins and suggest that the Rab geranylgeranyl transferase(s) requires recognition of protein conformation to signal the addition of geranylgeranyl groups. Finally, competition studies demonstrate that a common geranylgeranyl transferase activity is responsible for the modification of Rab proteins terminating in CC or CXC motifs.